Latest Strategic Outlook News

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Group 6 Metals has completed open cut mining at its Dolphin project, ramped up tungsten production to record levels, and secured new funding while preparing for underground operations.

MONEYME reported a robust start to FY26 with a 26% increase in its loan book and improved credit metrics, driven by strong originations and strategic product expansions.

Helios Energy has successfully completed its first oil sales following the restart of operations at its Presidio Oil Project in Texas, signaling a pivotal shift from exploration to production.

GoviEx Uranium Inc. securityholders have overwhelmingly approved a critical plan of arrangement, clearing a major hurdle for the proposed reverse takeover of Tombador Iron Limited. The transaction now moves closer to completion, pending final court approval.

Entertainment Rewards Ltd has secured significant amendments to its $22.5 million convertible loan agreement with Suzerain Investment Holdings, extending key deadlines to 2028 and enhancing its financial runway.

Magnetic Resources NL confirms a highly economic 9-year gold mining project at Lady Julie with a pre-tax NPV of A$970 million and strong funding momentum. The project is poised for construction readiness following key approvals and a successful $35 million placement.

Supply Network Limited reported robust FY2025 results with double-digit revenue growth, expanded capacity across Australia and New Zealand, and announced a new auditor appointment at its AGM.

Corporate Travel Management reports a 6% revenue increase and a 29% rise in EBITDA for 1QFY26, maintaining operational strength amid an ongoing audit review and trading suspension.

Ampol Limited has priced A$500 million of subordinated notes due 2055, refinancing existing debt and enhancing financial flexibility. The long-term capital raise attracted strong demand from regional fixed income investors.

Anatara Lifesciences reports steady progress in its anti-obesity pre-clinical studies with results expected by year-end, while preparing its GaRP gastrointestinal health data for publication amid ongoing commercial talks. The company also announces a key board appointment and a $1.2 million capital raise.

Lumos Diagnostics reported steady quarterly revenue with a 300% surge in product sales, driven by its flagship FebriDx® test. The company inked a landmark US$317 million exclusive U.S. distribution agreement and awaits FDA feedback on its CLIA waiver application.